Lymphoplasmacytic lymphoma epidemiology and demographics
|
Lymphoplasmacytic lymphoma Microchapters |
|
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphoplasmacytic lymphoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma epidemiology and demographics |
|
FDA on Lymphoplasmacytic lymphoma epidemiology and demographics |
|
CDC on Lymphoplasmacytic lymphoma epidemiology and demographics |
|
Lymphoplasmacytic lymphoma epidemiology and demographics in the news |
|
Blogs on Lymphoplasmacytic lymphoma epidemiology and demographics |
|
Risk calculators and risk factors for Lymphoplasmacytic lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
The prevalence of lymphoplasmacytic lymphoma is estimated to be 1000-1500 cases in United States annually. Lymphoplasmacytic lymphoma represents 1-2% of all hematological cancers.
Epidemiology and Demographics
- Lymphoplasmacytic lymphoma is one of the rare subtypes of NHL accounting just 1-2% of it.
Prevalence:
- The prevalence of lymphoplasmacytic lymphoma is estimated to be 1000-1,500 cases in United States annually.[1][2]
Incidence:
- LPL accounts for approximately 1% to 2% of hematologic cancers in United States and Western Europe.[3][2]
- World-wide, the overall age-adjusted incidence of lymphoplasmacytic lymphoma is 0.38 cases per 100,000 persons annually, increasing with age to 2.85 in patients above 80 years (or 5 cases per 1 million persons per year).[4]
- Incidence of LPL. is approximately 8.3 cases per million persons per year.[5]
- LPL incidence is approximately 10-fold lower in Asia.[6]
- Majority of LPL patients are Caucasians, with other ethnic groups accounting for only 5 percent of cases.[2]
- The age-adjusted incidence rate for males is 0.92 per 100,000 person-years.[7]
- The age-adjusted incidence rate for females is 0.30 per 100,000 person-years.[7]
- Combined age and sex-adjusted incidence is 0.57 per 100,000 person-years.[7]
Age:
- The incidence of lymphoplasmacytic lymphoma increases after 50 years of age.[8]
Gender:
- Men are twice more likely than women to develop LPL(5.4 vs. 2.7 per million, respectively). [1][9][10][3]
Race:
- Higher incidence in whites (4.1 per million per year) comparative to blacks (1.8 per million per year) and in past 20 years, incidence in whites has elevated.[1][9][5][3]
Epidemiology and demographics of Smoldering Waldenstrom macroglobulinemia:
According to a recent study done in 2017, the following data was found out regarding epidemiology and demographics of SWM.[11]
| Risk factors | Proportion of SWM |
|---|---|
| Sex | Males:27.72%, Females:28.31% |
| Race | White, non-hispanic:28.97%, White, Hispanic:24.79%, Black:21.01%, Asian:20.41%, Other:26.08%. |
| Age in years | 18-49:18.32%, 50-64:25.91%, 65-79:30.8%, ≥80 : 27.26% |
References
- ↑ 1.0 1.1 1.2 1.3 Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R; et al. (2012). "Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study". Cancer. 118 (15): 3793–800. doi:10.1002/cncr.26627. PMID 22139816.
- ↑ 2.0 2.1 2.2 Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF (1998). "Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994". Cancer. 82 (6): 1078–81. PMID 9506352.
- ↑ 3.0 3.1 3.2 3.3 Herrinton LJ, Weiss NS (1993). "Incidence of Waldenström's macroglobulinemia". Blood. 82 (10): 3148–50. PMID 8219203.
- ↑ Monge J, Braggio E, Ansell SM (2013). "Genetic factors and pathogenesis of Waldenström's macroglobulinemia". Curr Oncol Rep. 15 (5): 450–6. doi:10.1007/s11912-013-0331-7. PMC 3807757. PMID 23901022.
- ↑ 5.0 5.1 Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–76. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
- ↑ Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y; et al. (2014). "Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003". Int J Cancer. 134 (1): 174–80. doi:10.1002/ijc.28343. PMID 23784625.
- ↑ 7.0 7.1 7.2 Kyle, Robert A.; Larson, Dirk R.; McPhail, Ellen D.; Therneau, Terry M.; Dispenzieri, Angela; Kumar, Shaji; Kapoor, Prashant; Cerhan, James R.; Rajkumar, S. Vincent (2018). "Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review". Mayo Clinic Proceedings. 93 (6): 739–746. doi:10.1016/j.mayocp.2018.02.011. ISSN 0025-6196.
- ↑ Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
- ↑ 9.0 9.1 9.2 Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L; et al. (2017). "Waldenström Macroglobulinemia: Review of Pathogenesis and Management". Clin Lymphoma Myeloma Leuk. 17 (5): 252–262. doi:10.1016/j.clml.2017.02.028. PMC 5413391. PMID 28366781.
- ↑ Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H; et al. (2007). "Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus". JAMA. 297 (18): 2010–7. doi:10.1001/jama.297.18.2010. PMID 17488966.
- ↑ Pophali, Priyanka Avinash; Bartley, Adam C.; Kapoor, Prashant; Gonsalves, Wilson I.; Ashrani, Aneel A.; Marshall, Ariela L.; Siddiqui, Mustaqeem Ahmad; Go, Ronald S. (2017). "Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB)". Journal of Clinical Oncology. 35 (15_suppl): 1573–1573. doi:10.1200/JCO.2017.35.15_suppl.1573. ISSN 0732-183X.